Biocon Phase III data on switching biosimilar aflibercept
Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed biosimilar to ophthalmic drug aflibercept, which is marketed by Germany’s Bayer (BAYN: DE) under the trade name Eylea.
Regeneron (Nasdaq: REGN), which developed aflibercept and licensed it to Bayer, has been in legal battles with other companies developing biosimilars, including Sandoz (SWX: SDZ) and Samsung Bioepis. Regeneron has had some success in court in recent months, with a judge in West Virginia granting a permanent injunction preventing Biocon Biologics from marketing its Eylea biosimilar, Yesafili (aflibercept-jbvf).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze